These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33088577)

  • 21. Evaluation of community pharmacists' readiness to implement the Falsified Medicines Directive (Directive 2011/62/EC): an English cross-sectional survey with geospatial analysis.
    Barrett R
    BMJ Open; 2020 Jan; 10(1):e033405. PubMed ID: 31924640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011).
    Almuzaini T; Sammons H; Choonara I
    BMJ Open; 2013; 3(7):. PubMed ID: 23883882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Swedish community pharmacy employees' knowledge and experience of substandard and falsified medical products: a cross-sectional descriptive survey.
    Persson A; Troein M; Lundin S; Midlöv P; Lenander C
    Int J Pharm Pract; 2022 Nov; 30(5):414-419. PubMed ID: 35849136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The capacity of young national medicine regulatory authorities to ensure the quality of medicines: case of Rwanda.
    Shabani JBB; Kayitare E; Nyirimigabo E; Habyalimana V; Murindahabi MM; Ntirenganya L; Irasabwa C; Rutungwa E; Munyangaju JE; Hahirwa I
    J Pharm Policy Pract; 2022 Nov; 15(1):90. PubMed ID: 36434730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa.
    Kusynová Z; Bais Y; van den Ham HA; Mantel-Teeuwisse AK; Etame-Loe G; Kaale E; Sarr SO; Guiet-Mati F; Bourdillon-Esteve P
    BMJ Glob Health; 2023 Feb; 6(Suppl 3):. PubMed ID: 36731919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing health system strengthening through improving access to medicines: A review of local manufacturing policies in Ghana.
    Peprah Boaitey K; Tuck C
    Med Access Point Care; 2020; 4():2399202620962299. PubMed ID: 36204087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
    Mori AT; Meena E; Kaale EA
    BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of substandard and falsified artemisinin-based combination antimalarial medicines on Bioko Island, Equatorial Guinea.
    Kaur H; Allan EL; Mamadu I; Hall Z; Green MD; Swamidos I; Dwivedi P; Culzoni MJ; Fernandez FM; Garcia G; Hergott D; Monti F
    BMJ Glob Health; 2017; 2(4):e000409. PubMed ID: 29082025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation.
    Narsai K; Masekela FB; Leufkens HGM; Mantel-Teeuwisse AK
    BMC Health Serv Res; 2024 Jan; 24(1):111. PubMed ID: 38245720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An exploratory assessment of the legislative framework for combating counterfeit medicines in South Africa.
    Moshoeshoe RJ; Enslin GM; Katerere DR
    J Pharm Policy Pract; 2022 Jan; 15(1):3. PubMed ID: 34986899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches.
    Ozawa S; Higgins CR; Nwokike JI; Phanouvong S
    Am J Trop Med Hyg; 2022 Jul; 107(1):14-20. PubMed ID: 35895357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.
    Pisani E; Nistor AL; Hasnida A; Parmaksiz K; Xu J; Kok MO
    Wellcome Open Res; 2019; 4():70. PubMed ID: 31131333
    [No Abstract]   [Full Text] [Related]  

  • 35. Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries.
    Rasheed H; Höllein L; Holzgrabe U
    Front Pharmacol; 2018; 9():995. PubMed ID: 30233373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The scourge of substandard and falsified medical products gets worse with COVID-19 pandemic.
    Shiferie F; Kassa E
    Pan Afr Med J; 2020; 37():344. PubMed ID: 33738032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab.
    Gnegel G; Häfele-Abah C; Neci R; ; Heide L
    Sci Rep; 2022 Jul; 12(1):13095. PubMed ID: 35908047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Falsified and substandard medicines trafficking: A wakeup call for the African continent.
    Wada YH; Abdulrahman A; Ibrahim Muhammad M; Owanta VC; Chimelumeze PU; Khalid GM
    Public Health Pract (Oxf); 2022 Jun; 3():100240. PubMed ID: 36101748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Epidemic of Substandard and Falsified Medications in Iraq: Evaluating the Effectiveness of National Pharmacovigilance Alerts to Community Pharmacies.
    Al-Jumaili AA; Younus MM; Saleh MZ
    Pharmaceut Med; 2021 May; 35(3):169-186. PubMed ID: 33864206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying and costing common gaps in Central and West Africa pharmaceutical regulation.
    Alfonso CP; N'Jambong GB; Magdy A; Di Trapani L; Kuwana R; Kahsay AG; Maïga D; Ossei-Agyeman-Yeboah SNA; Djitafo Fah AB; Ndomondo-Sigonda M
    Front Med (Lausanne); 2024; 11():1362253. PubMed ID: 38660423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.